Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

Original reporting
Published Nov 17, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision — source image
Decision brief

The 30-second read

$AQSTNeutralMed
01

Why it matters

The key trading angle is whether the FDA has already indicated no greater cardiovascular risk versus auto-injectors, which can improve approval odds and reduce tail-risk. However, the company still lacks the exact rationale for observed blood-pressure response differences and expects post-marketing real-world evidence commitments after approval.

02

Market read

Regulatory risk framing and launch planning details can shift probability-weighting for approval, but the absence of a pricing decision and reliance on post-marketing evidence limit near-term certainty.

03

What to watch

No Anaphylm pricing is set, insurer discussions are preliminary, and the company’s sales plan depends on payer acceptance and real-world evidence design after approval.

Relevance 7/10Novelty 6/10Timing: ahead of the next FDA decision window, with launch planning discussed

Background

Aquestive is developing Anaphylm, a needle-free epinephrine film intended to treat severe allergic reactions, and is outlining clinical and regulatory expectations ahead of a 2027 FDA decision.

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

Aquestive discusses Anaphylm clinical absorption and blood-pressure effects, plus FDA-written guidance on cardiovascular risk, shaping the 2027 decision outlook.

Expected impact

Shares may see modest upside bias as the market weighs reduced cardiovascular-risk concerns, tempered by remaining unanswered clinical-rationale questions.

Evidence & confidence

The article provides specific FDA-related statements and trial preference/PK timing, but it does not report an approval, new endpoint, or a fresh regulatory milestone beyond expectations.

Market effects

Highlights competitive pressure in severe allergic reaction therapeutics and needle-free delivery, potentially affecting sentiment toward other epinephrine delivery platforms.

US launch planning and Canada/Europe/UK filing timelines may influence regional biotech/rare-allergy investor positioning.

Cross-region regulatory filing cadence (Canada, Europe, UK) can affect global expectations for needle-free epinephrine adoption.

Counterpoint

The article emphasizes theories and pending post-marketing commitments, so the FDA cardiovascular reassurance may not eliminate residual efficacy or safety concerns that could delay approval.

Key entities

  • Aquestive Therapeutics

    NASDAQ-listed developer of PharmFilm drug-delivery technology, including Anaphylm for severe allergic reactions.

  • Anaphylm

    Needle-free allergy treatment film discussed with absorption timing and blood-pressure response comparisons to auto-injectors.

  • Eton Pharmaceuticals

    Partner mentioned for Libervant in the U.S.

  • Libervant

    Diazepam buccal film for seizure clusters, described as tentatively approved and awaiting orphan exclusivity expiration.

Related articles

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.